Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria

Susan A. Charman, Sarah Arbe-Barnes, Ian C. Bathurst, Reto Brund, Michael Campbell, William N. Charman, Francis C.K. Chiu, Jacques Chollet, J. Carl Craft, Darren J. Creek, Yuxiang Dong, Hugues Matile, Melanie Maurer, Julia Morizzi, Tien Nguyen, Petros Papastogiannidis, Christian Scheurer, David M. Shackleford, Kamaraj Sriraghavan, Lukas Stingelin & 7 others Yuanqing Tang, Heinrich Urwyler, Xiaofang Wang, Karen L. White, Sergio Wittlin, Lin Zhou, Jonathan L Vennerstrom

Research output: Contribution to journalArticle

239 Citations (Scopus)

Abstract

Ozonide OZ439 is a synthetic peroxide antimalarial drug candidate designed to provide a single-dose oral cure in humans. OZ439 has successfully completed Phase I clinical trials, where it was shown to be safe at doses up to 1,600 mg and is currently undergoing Phase IIa trials in malaria patients. Herein, we describe the discovery of OZ439 and the exceptional antimalarial and pharmacokinetic properties that led to its selection as a clinical drug development candidate. In vitro, OZ439 is fast-acting against all asexual erythrocytic Plasmodium falciparum stages with IC50 values comparable to those for the clinically used artemisinin derivatives. Unlike all other synthetic peroxides and semisynthetic artemisinin derivatives, OZ439 completely cures Plasmodium berghei-infected mice with a single oral dose of 20 mg/kg and exhibits prophylactic activity superior to that of the benchmark chemoprophylactic agent, mefloquine. Compared with other peroxide-containing antimalarial agents, such as the artemisinin derivatives and the first-generation ozonide OZ277, OZ439 exhibits a substantial increase in the pharmacokinetic half-life and blood concentration versus time profile in three preclinical species. The outstanding efficacy and prolonged blood concentrations of OZ439 are the result of a design strategy that stabilizes the intrinsically unstable pharmacophoric peroxide bond, thereby reducing clearance yet maintaining the necessary Fe (II)-reactivity to elicit parasite death.

Original languageEnglish (US)
Pages (from-to)4400-4405
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume108
Issue number11
DOIs
StatePublished - Mar 15 2011

Fingerprint

Peroxides
Malaria
Antimalarials
Pharmaceutical Preparations
Pharmacokinetics
Mefloquine
Plasmodium berghei
Benchmarking
Clinical Trials, Phase I
Plasmodium falciparum
Inhibitory Concentration 50
Half-Life
Parasites
1,2,4-trioxane
artemisinine

Keywords

  • 1,2,4-trioxolane
  • Antimalarial drug discovery

ASJC Scopus subject areas

  • General

Cite this

Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. / Charman, Susan A.; Arbe-Barnes, Sarah; Bathurst, Ian C.; Brund, Reto; Campbell, Michael; Charman, William N.; Chiu, Francis C.K.; Chollet, Jacques; Craft, J. Carl; Creek, Darren J.; Dong, Yuxiang; Matile, Hugues; Maurer, Melanie; Morizzi, Julia; Nguyen, Tien; Papastogiannidis, Petros; Scheurer, Christian; Shackleford, David M.; Sriraghavan, Kamaraj; Stingelin, Lukas; Tang, Yuanqing; Urwyler, Heinrich; Wang, Xiaofang; White, Karen L.; Wittlin, Sergio; Zhou, Lin; Vennerstrom, Jonathan L.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 108, No. 11, 15.03.2011, p. 4400-4405.

Research output: Contribution to journalArticle

Charman, SA, Arbe-Barnes, S, Bathurst, IC, Brund, R, Campbell, M, Charman, WN, Chiu, FCK, Chollet, J, Craft, JC, Creek, DJ, Dong, Y, Matile, H, Maurer, M, Morizzi, J, Nguyen, T, Papastogiannidis, P, Scheurer, C, Shackleford, DM, Sriraghavan, K, Stingelin, L, Tang, Y, Urwyler, H, Wang, X, White, KL, Wittlin, S, Zhou, L & Vennerstrom, JL 2011, 'Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria', Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 11, pp. 4400-4405. https://doi.org/10.1073/pnas.1015762108
Charman, Susan A. ; Arbe-Barnes, Sarah ; Bathurst, Ian C. ; Brund, Reto ; Campbell, Michael ; Charman, William N. ; Chiu, Francis C.K. ; Chollet, Jacques ; Craft, J. Carl ; Creek, Darren J. ; Dong, Yuxiang ; Matile, Hugues ; Maurer, Melanie ; Morizzi, Julia ; Nguyen, Tien ; Papastogiannidis, Petros ; Scheurer, Christian ; Shackleford, David M. ; Sriraghavan, Kamaraj ; Stingelin, Lukas ; Tang, Yuanqing ; Urwyler, Heinrich ; Wang, Xiaofang ; White, Karen L. ; Wittlin, Sergio ; Zhou, Lin ; Vennerstrom, Jonathan L. / Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. In: Proceedings of the National Academy of Sciences of the United States of America. 2011 ; Vol. 108, No. 11. pp. 4400-4405.
@article{96c5a9fa15394b84ad46f86a2157a41b,
title = "Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria",
abstract = "Ozonide OZ439 is a synthetic peroxide antimalarial drug candidate designed to provide a single-dose oral cure in humans. OZ439 has successfully completed Phase I clinical trials, where it was shown to be safe at doses up to 1,600 mg and is currently undergoing Phase IIa trials in malaria patients. Herein, we describe the discovery of OZ439 and the exceptional antimalarial and pharmacokinetic properties that led to its selection as a clinical drug development candidate. In vitro, OZ439 is fast-acting against all asexual erythrocytic Plasmodium falciparum stages with IC50 values comparable to those for the clinically used artemisinin derivatives. Unlike all other synthetic peroxides and semisynthetic artemisinin derivatives, OZ439 completely cures Plasmodium berghei-infected mice with a single oral dose of 20 mg/kg and exhibits prophylactic activity superior to that of the benchmark chemoprophylactic agent, mefloquine. Compared with other peroxide-containing antimalarial agents, such as the artemisinin derivatives and the first-generation ozonide OZ277, OZ439 exhibits a substantial increase in the pharmacokinetic half-life and blood concentration versus time profile in three preclinical species. The outstanding efficacy and prolonged blood concentrations of OZ439 are the result of a design strategy that stabilizes the intrinsically unstable pharmacophoric peroxide bond, thereby reducing clearance yet maintaining the necessary Fe (II)-reactivity to elicit parasite death.",
keywords = "1,2,4-trioxolane, Antimalarial drug discovery",
author = "Charman, {Susan A.} and Sarah Arbe-Barnes and Bathurst, {Ian C.} and Reto Brund and Michael Campbell and Charman, {William N.} and Chiu, {Francis C.K.} and Jacques Chollet and Craft, {J. Carl} and Creek, {Darren J.} and Yuxiang Dong and Hugues Matile and Melanie Maurer and Julia Morizzi and Tien Nguyen and Petros Papastogiannidis and Christian Scheurer and Shackleford, {David M.} and Kamaraj Sriraghavan and Lukas Stingelin and Yuanqing Tang and Heinrich Urwyler and Xiaofang Wang and White, {Karen L.} and Sergio Wittlin and Lin Zhou and Vennerstrom, {Jonathan L}",
year = "2011",
month = "3",
day = "15",
doi = "10.1073/pnas.1015762108",
language = "English (US)",
volume = "108",
pages = "4400--4405",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "11",

}

TY - JOUR

T1 - Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria

AU - Charman, Susan A.

AU - Arbe-Barnes, Sarah

AU - Bathurst, Ian C.

AU - Brund, Reto

AU - Campbell, Michael

AU - Charman, William N.

AU - Chiu, Francis C.K.

AU - Chollet, Jacques

AU - Craft, J. Carl

AU - Creek, Darren J.

AU - Dong, Yuxiang

AU - Matile, Hugues

AU - Maurer, Melanie

AU - Morizzi, Julia

AU - Nguyen, Tien

AU - Papastogiannidis, Petros

AU - Scheurer, Christian

AU - Shackleford, David M.

AU - Sriraghavan, Kamaraj

AU - Stingelin, Lukas

AU - Tang, Yuanqing

AU - Urwyler, Heinrich

AU - Wang, Xiaofang

AU - White, Karen L.

AU - Wittlin, Sergio

AU - Zhou, Lin

AU - Vennerstrom, Jonathan L

PY - 2011/3/15

Y1 - 2011/3/15

N2 - Ozonide OZ439 is a synthetic peroxide antimalarial drug candidate designed to provide a single-dose oral cure in humans. OZ439 has successfully completed Phase I clinical trials, where it was shown to be safe at doses up to 1,600 mg and is currently undergoing Phase IIa trials in malaria patients. Herein, we describe the discovery of OZ439 and the exceptional antimalarial and pharmacokinetic properties that led to its selection as a clinical drug development candidate. In vitro, OZ439 is fast-acting against all asexual erythrocytic Plasmodium falciparum stages with IC50 values comparable to those for the clinically used artemisinin derivatives. Unlike all other synthetic peroxides and semisynthetic artemisinin derivatives, OZ439 completely cures Plasmodium berghei-infected mice with a single oral dose of 20 mg/kg and exhibits prophylactic activity superior to that of the benchmark chemoprophylactic agent, mefloquine. Compared with other peroxide-containing antimalarial agents, such as the artemisinin derivatives and the first-generation ozonide OZ277, OZ439 exhibits a substantial increase in the pharmacokinetic half-life and blood concentration versus time profile in three preclinical species. The outstanding efficacy and prolonged blood concentrations of OZ439 are the result of a design strategy that stabilizes the intrinsically unstable pharmacophoric peroxide bond, thereby reducing clearance yet maintaining the necessary Fe (II)-reactivity to elicit parasite death.

AB - Ozonide OZ439 is a synthetic peroxide antimalarial drug candidate designed to provide a single-dose oral cure in humans. OZ439 has successfully completed Phase I clinical trials, where it was shown to be safe at doses up to 1,600 mg and is currently undergoing Phase IIa trials in malaria patients. Herein, we describe the discovery of OZ439 and the exceptional antimalarial and pharmacokinetic properties that led to its selection as a clinical drug development candidate. In vitro, OZ439 is fast-acting against all asexual erythrocytic Plasmodium falciparum stages with IC50 values comparable to those for the clinically used artemisinin derivatives. Unlike all other synthetic peroxides and semisynthetic artemisinin derivatives, OZ439 completely cures Plasmodium berghei-infected mice with a single oral dose of 20 mg/kg and exhibits prophylactic activity superior to that of the benchmark chemoprophylactic agent, mefloquine. Compared with other peroxide-containing antimalarial agents, such as the artemisinin derivatives and the first-generation ozonide OZ277, OZ439 exhibits a substantial increase in the pharmacokinetic half-life and blood concentration versus time profile in three preclinical species. The outstanding efficacy and prolonged blood concentrations of OZ439 are the result of a design strategy that stabilizes the intrinsically unstable pharmacophoric peroxide bond, thereby reducing clearance yet maintaining the necessary Fe (II)-reactivity to elicit parasite death.

KW - 1,2,4-trioxolane

KW - Antimalarial drug discovery

UR - http://www.scopus.com/inward/record.url?scp=79952732772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952732772&partnerID=8YFLogxK

U2 - 10.1073/pnas.1015762108

DO - 10.1073/pnas.1015762108

M3 - Article

VL - 108

SP - 4400

EP - 4405

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 11

ER -